LSL Pharma Group (TSXV:LSL) Mohanram G-Score: N/A (As of Mar. 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
50 GF Score
Price C$0.30
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Mohanram G-Score?

LSL Pharma Group does not have enough data to calculate Mohanram G-Score.

LSL Pharma Group  (TSXV:LSL) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


LSL Pharma Group Mohanram G-Score Related Terms


LSL Pharma Group Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Mohanram G-Score Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

TSXV:LSL vs ZTS: Mohanram G-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LSL Pharma Group Mohanram G-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where LSL Pharma Group's Mohanram G-Score falls into.


TSXV:LSL
50GF Score
LSL Pharma Group Inc TSXV:LSL
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.30 is trading 58.3% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Mohanram G-Score: N/A
  • GF Value™: C$0.72 vs. price of C$0.30 (58.3% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score

Get the complete analysis for TSXV:LSL

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.30
Price
C$0.72
GF Value